Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023 (Q27614)
Jump to navigation
Jump to search
No description defined
- Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults - United States, August 2022-July 2023.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023 |
No description defined |
|
Statements
A global outbreak of clade II mpox associated with sexual contact, disproportionately affecting gay, bisexual, and other men who have sex with men (MSM), has been ongoing since May 2022. (English)
Information on types of contact most associated with transmission is limited. (English)
This report used data from a multijurisdictional vaccine effectiveness case-control study of sexually active persons aged 18-49 years who identified as MSM or transgender, collected during August 2022-July 2023. (English)
Odds of mpox associated with selected types of intimate and nonintimate close contact with a person with mpox were estimated. (English)
Among 457 case-patients and 1,030 control patients who met minimum data requirements, 150 (32.8%) case-patients and 57 (5.5%) control patients reported close contact with a person with mpox and were included in this analysis. (English)
Adjusted odds of mpox were 5.4 times as high among those who reported having condomless receptive anal sex with a person with mpox, compared with participants who reported close contact with a person with mpox and no condomless receptive anal sex with that person (OR = 5.4; p = 0.031). (English)
Although the mpox vaccine is highly effective, vaccination coverage remains low; a multifaceted approach to prevention remains important and should include vaccination promotion, safer sex practices, and increasing awareness that mpox continues to circulate. (English)
Anna N (English)
Chard (English)
AN
Alexandra F (English)
Dalton (English)
AF
Alpha Oumar (English)
Diallo (English)
AO
Danielle L (English)
Moulia (English)
DL
Nicholas P (English)
Deputy (English)
NP
Italo B (English)
Zecca (English)
IB
Laura A S (English)
Quilter (English)
LAS
Rachel E (English)
Kachur (English)
RE
Andrea M (English)
McCollum (English)
AM
Jemma V (English)
Rowlands (English)
JV
Amber N (English)
Britton (English)
AN
Rebecca (English)
Fisher (English)
R
Shua J (English)
Chai (English)
SJ
Erin (English)
Licherdell (English)
E
William L (English)
Still (English)
WL
Adeline L (English)
Morris (English)
AL
Jessica L (English)
Castilho (English)
JL
Tiffanie M (English)
Markus (English)
TM
Allison S (English)
Morrow (English)
AS
Phoebe (English)
Danza (English)
P
AmberJean P (English)
Hansen (English)
AP
Sophia Ibrahim (English)
Ali (English)
SI
Christopher W (English)
Wegner (English)
CW
Robyn (English)
Weber (English)
R
Gabriela S (English)
Betancourt (English)
GS
Jennifer (English)
Zipprich (English)
J
Melissa (English)
Sutton (English)
M
Preeti (English)
Pathela (English)
P
Sam (English)
Hawkins (English)
S
Karen A (English)
Wendel (English)
KA
Leora R (English)
Feldstein (English)
LR
12 October 2024
10 October 2024
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. (English)
Jessica L. Castilho reports support from Copan Diagnostics. (English)
Karen A. Wendel reports institutional support from Hologic Inc and an unpaid leadership role in the Denver Metro Sexually Transmitted Infections Coalition. (English)
Jennifer Zipprich reports spousal employment at Pfizer. (English)
No other potential conflicts of interest were disclosed. (English)